OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer

被引：0
|
作者：
Nicum, S. [1 ]
Strauss, V. Y. [2 ]
McGregor, N. [3 ]
McNeish, I. [4 ]
Roux, R. [1 ]
Hall, M. [5 ]
Michael, A. [6 ]
Roberts, C. [2 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England
[2] Univ Oxford, Ctr Stat Med, Oxford, England
[3] Univ Oxford, Dept Oncol, Oncol Clin Trials Off, Oxford, England
[4] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland
[5] East & North Hertfordshire NHS Trust, Mt Vernon Canc Ctr, Stevenage, Middx, England
[6] Univ Surrey, Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
989TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
    Lieberman, Howard B.
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 418 - 420
  • [22] Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
    Le, Dan
    Gelmon, Karen A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (09) : 833 - 839
  • [23] A phase II/III study of cediranib and olaparib combination compared to cediranib or olaparib alone or standard of care chemotherapy, in platinum-resistant ovarian cancer (NRG-GY005)
    Lee, Jung-Min
    Mark, Brady
    Miller, Austin
    Moore, Richard
    Mackay, Helen
    McNally, Leah
    Lea, Jayanthi
    Street, Daron
    Lheureux, Stephanie
    Bender, David
    Duska, Linda
    Cantuaria, Guilherme
    Kavecansky, Juraj
    Leath, Charles
    Powell, Matthew
    Cadungog, Mark
    Rose, Peter
    Bookman, Michael
    Kohn, Elise
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S13 - S13
  • [24] COPELIA: a 3-arm randomised phase II trial of weekly paclitaxel with or without cediranib or olaparib with cediranib in recurrent endometrial cancer
    Clamp, Andrew R.
    Porter, Catharine
    White, Ann
    Irving, Alys
    Casbard, Angela
    Hall, Marcia
    Eminowicz, Gemma
    George, Angela
    Walther, Axel
    Franklin, Adrian
    Sadozye, Azmat
    Hanna, Louise
    Hughes, Andrew
    Roux, Rene
    Lord, Rosemary
    Bowen, Rebecca
    Wood, Joey
    Sentamans, Clara
    Kristeleit, Rebecca
    Jayson, Gordon C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A17 - A18
  • [25] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
    Liu, Joyce F.
    Barry, William T.
    Birrer, Michael
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rimel, B. J.
    Buss, Mary K.
    Nattam, Sreenivasa
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Whalen, Christin
    Obermayer, Lisa
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula A.
    LANCET ONCOLOGY, 2014, 15 (11): : 1207 - 1214
  • [26] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
    Velev, Maud
    Puszkiel, Alicja
    Blanchet, Benoit
    de Percin, Sixtine
    Delanoy, Nicolas
    Medioni, Jacques
    Gervais, Claire
    Balakirouchenane, David
    Khoudour, Nihel
    Pautier, Patricia
    Leary, Alexandra
    Ajgal, Zahra
    Hirsch, Laure
    Goldwasser, Francois
    Alexandre, Jerome
    Beinse, Guillaume
    PHARMACEUTICALS, 2021, 14 (08)
  • [28] Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain
    Moya-Alarcon, Carlota
    Gonzalez-Dominguez, Almudena
    Ivanova-Markova, Yoana
    Gimeno-Ballester, Vicente
    Barretina-Ginesta, Maria-Pilar
    Alejandro Perez-Fidalgo, Jose
    Redondo, Andres
    GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 406 - 414
  • [29] Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Wu, Bin
    Shi, Lizheng
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (11): : 1528 - +
  • [30] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
    Penson, R. T.
    Valencia, R. V.
    Cibula, D.
    Colombo, N.
    Ill, C. L.
    Bidzinski, M.
    Kim, J. W.
    Nam, J. H.
    Madry, R.
    Hernandez, C. H.
    Mora, P.
    Ryu, S. Y.
    Milenkova, T.
    Lowe, E.
    Barker, L.
    Scambia, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
12345